Roche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduct...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

GlaxoSmithKline Pharmaceuticals is planning a major comeback in India. The company aims to double its revenue to ₹8,000 crore within the ne...

New data from Europe's biggest oncology meeting reveals a high-stakes race for patients with a tough breast cancer. Astra and Daiichi's Dat...

GlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. Thes...

Russia's Gamaleya Center, famed for Sputnik V, will initiate human trials for a personalized mRNA melanoma vaccine by late 2025. This innov...

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...

Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for advanced cuta...

Mankind Pharma has partnered with Innovent Biologics to bring sintilimab, a PD-1 immunotherapy, to India. The drug treats various cancers a...

Aurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with mul...

In India, cervical cancer is the second most common in women, making up close to 18 per cent of the new cancer cases, the International Age...

Amrita Hospital's Department of Hematology, Medical Oncology and BMT helps patients treat blood disorders, benign diseases, as well as bloo...

"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to off...

WHO estimates at least 2.8 million people die each year as a result of being overweight or obese.

Immunotherapy should be given as early as possible to achieve a lasting remission of the disease.

Merck is betting big on its oncology pipeline, in the field of immunotherapy that has come to define new-age cancer treatment.

Under the terms of the agreement, Glenmark will license the product from APC Therapeutics and manage all clinical development, including re...